Emcure Pharmaceuticals has entered into a distribution agreement with Roche India for select products in nephrology and transplantation, marking a strategic step in expanding patient access to critical therapies across India.
The agreement includes three key Roche brands — CellCept, an immunosuppressant for transplant care, and Mirceraand NeoRecormon, both proven therapies for anaemia management in Chronic Kidney Disease (CKD) patients.
Emcure MD & CEO Satish Mehta stated that the partnership reflects the company’s deep commitment to renal and anaemia care, aiming to deliver optimal outcomes for patients nationwide.
Roche India MD & CEO Rajji Mehdiratta expressed confidence in Emcure’s strong distribution network and nephrology expertise, enabling wider reach for Roche’s innovative CKD portfolio.
Together, the two companies aim to bridge critical therapy access gaps and improve standards of care in nephrology and transplantation across India.
Written by: Srabanti Bhattacharjee
Graphics by: Pramit Hazra
